Early T cell activation in the skin from patients with systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 64, Issue 8, 2005, Pages 1233-1235

  Kalogerou, A ^a   Gelou, E ^a   Mountantonakis, S ^a   Settas, L ^b   Zafiriou, E ^a   Sakkas, L ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD68 ANTIGEN; CD69 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROBLAST; FIBROSIS; HUMAN; IMMUNOPEROXIDASE STAINING; INFLAMMATORY CELL; MACROPHAGE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN; T-LYMPHOCYTE SUBSETS;

EID: 23444457756     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.027094     Document Type: Article

References (15)

1. Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? Arthrtis Rheum 2004;50:1721-33.
2. Fiocco U, Rosada M, Cozzi L, Ortolani C, de Silvestra G, Ruffati A, et al. Early phenotypic activation of circulating helper memory T cells in scleroderma : correlation with disease activity. Ann Rheum Dis 1993;52:272-7.
3. Sondergaard K, Stengaard-Pedersen K, Zachariae H, Heickendorff L, Deleuran M, Deleuran B. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Br J Rheumatol 1998;37:304-10.
4. Needleman BW, Wigley FM, Stair RW. lnterleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
5. Sakkos LI, Tourtelotte C, Myers A, Berney S, Platsoucas CD. Increased levels of alternatively spliced interleukin-4 (IL-4δ2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin Diagn Lab Immunol 1999;6:660-4.
6. Kurosawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum, 2000;43, 2455-63.
7. Roum AD, Whiteside TL, Medger TA Jr, Rodman GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
8. Prescott RJ, Freemont AJ, Jones CSP, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
9. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168:3649-59.
10. Testi R, Phillips JR, Lanier LL. Leu23 induction as an early marker of functional CD3/T cell antigen receptor triggering. J Immunol 1989;142:1854-60.
11. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of inter-observer variability in three independent studies. J Rheumatol 1993;20:1892-6.
12. Isler P, Vey E, Zhang JH, Dayer JM. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw 1993;4:15-23.
13. Black C, Dieppe P, Huskisson T, Hart FD. Regressive systemic sclerosis. Ann Rheum Dis 1986;45:384-8.
14. Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, et al. Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993;36:75-83.
15. Morton SJ, Powell RJ. Cyclosporine and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford) 2000;39:865-9.